STERIS (NYSE:STE - Get Free Report) is anticipated to announce its Q4 2025 earnings results after the market closes on Wednesday, May 14th. Analysts expect the company to announce earnings of $2.58 per share and revenue of $1.47 billion for the quarter.
STERIS (NYSE:STE - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.33 by ($0.01). STERIS had a net margin of 8.66% and a return on equity of 13.91%. On average, analysts expect STERIS to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.
STERIS Trading Down 0.9 %
STE stock opened at $222.23 on Wednesday. The company has a quick ratio of 1.40, a current ratio of 2.13 and a debt-to-equity ratio of 0.32. The company has a market cap of $21.83 billion, a price-to-earnings ratio of 47.18 and a beta of 0.96. The business has a fifty day simple moving average of $223.19 and a 200-day simple moving average of $218.78. STERIS has a 52 week low of $200.98 and a 52 week high of $248.24.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on the company. JMP Securities reiterated a "market outperform" rating and set a $265.00 target price on shares of STERIS in a report on Thursday, April 10th. Stephens upgraded shares of STERIS to a "strong-buy" rating in a report on Thursday, May 1st. Piper Sandler raised their price objective on STERIS from $260.00 to $265.00 and gave the company an "overweight" rating in a research report on Monday, February 3rd. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of STERIS in a research report on Monday, April 7th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, STERIS has a consensus rating of "Buy" and a consensus price target of $258.75.
Read Our Latest Analysis on STE
STERIS Company Profile
(
Get Free Report)
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider STERIS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.
While STERIS currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
